Background Vorapaxar is a new oral protease-activated–receptor 1 (PAR-1) antagonist that
inhibits thrombin-induced platelet activation. Methods In this multinational, double-blind, …

Background An antithrombotic drug is needed that safely reduces cardiovascular events in
patients undergoing percutaneous coronary intervention (PCI). We therefore assessed the …

Objective Subcutaneous (SC) and intravenous formulations of tocilizumab (TCZ) are
available for the treatment of patients with rheumatoid arthritis (RA), based on the efficacy and …

Background Placebo-controlled clinical trials have demonstrated the efficacy of tocilizumab (TCZ)
for remission maintenance and glucocorticoid sparing in patients with giant cell …

Objective To evaluate whether tocilizumab ( TCZ ) monotherapy is noninferior to treatment
with TCZ plus methotrexate ( MTX ) for maintaining clinical responses in patients with …

Objective The objective of this study was to determine the impact of multiple sclerosis (MS)
disease‐modifying therapies (DMTs) on the development of cellular and humoral immunity to …

Background: Upper extremity (UE) impairment is common with primary progressive multiple
sclerosis (PPMS). Objective: This exploratory analysis examined the effects of ocrelizumab …

Objective To compare “hybrid immunity” (prior COVID‐19 infection plus vaccination) and
post‐vaccination immunity to SARS CoV‐2 in MS patients on different disease‐modifying …

Background Patients with radiologically isolated syndrome (RIS) exhibit CNS lesions suggestive
of multiple sclerosis (MS) in the absence of overt neurological symptoms characteristic …

Introduction Patients with rheumatoid arthritis (RA) have decreased survival because of
increased cardiovascular risk compared with the general population, and treatment with …